

Publication list of Dr. Timothy Y Y Lai

Total no. of journal articles: 241 (as of March 2020)

(* as corresponding author)

Citation metrics as of 15 March 2020:

Web of Science: Sum of Times Cited: 6828; h-index: 44

ResearchGate: Total Citations: 8220; h-index 50

Google Scholar: Total Citations: 10666; h-index: 56

1. Hamilton RD, Clemens A, Minnella AM, **Lai TY**, Dai H, Sakamoto T, Cheung CM, Ngah NF, Dunger-Baldauf C, Holz FG. Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS Study. *PLoS One*. 2020 Jan 21;15(1):e0227557.
2. Zhang X, **Lai TYY***. Impact of LEAVO Study in Asia. *Eye (Lond)*. 2020 Feb;34(2):211-212.
3. Liu K, Ma L, **Lai TYY**, Brelen ME, Tam POS, Tham CC, Pang CP, Chen LJ. Evaluation of the association of C5 with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. *Eye Vis (Lond)*. 2019 Nov 7;6:34. doi: 10.1186/s40662-019-0161-2. eCollection 2019.
4. Koh A, **Lai TYY**, Wei WB, Mori R, Wakiyama H, Park KH, Ngah F, Macfadden W, Dunger-Baldauf C, Parikh S. Real-world effectiveness and safety of ranibizumab treatment in patients with and without polypoidal choroidal vasculopathy: twelve-month results from the LUMINOUS Study. *Retina*. 2019 Aug 2. doi: 10.1097/IAE.0000000000002624. [Epub ahead of print]
5. Ma L, Ng TK, Brelen M, **Lai TY**, Ho M, Tam PO, Young A, Chen W, Tham C, Pang CP, Chen LJ. Identification and characterization of a novel promoter variant in placental growth factor for neovascular age-related macular degeneration. *Exp Eye Res*. 2019 Oct;187:107748. doi: 10.1016/j.exer.2019.107748
6. Ho M, Chen LJ, Sin HPY, Lu LPL, Brelen M, Ho ACH, **Lai TYY**, Young AL. Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease related uveitis. *J Ophthalmic Inflamm Infect*. 2019 Jul 31;9(1):14.
7. van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, **Lai TYY**, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF. Central serous chorioretinopathy: towards and evidence-based treatment guideline. *Prog Retin Eye Res*. 2019 Jul 15. pii: S1350-9462(18)30094-6. Doi:10.1016/j.preteyeres.2019.07.003 [Epub ahead of print]
8. Saxena S, **Lai TY**, Koizumi H, Farah ME, Ferrara D, Pelayes D, Sato T, Meyer CH, Murray T; International Pharmacokinetic Collaboration. Anterior chamber paracentesis during intravitreal

injections in observational trials: effectiveness and safety and effects. *Int J Retina Vitreous* 2019 Mar 6; 5:8. doi: 10.1186/s40942-019-0157-z.

9. Ho CPS, **Lai TYY***. Pharmacotherapy for choroidal neovascularization due to uncommon causes. *Curr Pharm Des* 2018;24(41):4882-4895.
10. **Lai TYY***, Cheung CMG. Asian perspective of eye diseases. *Eye (Lond)*. 2018 Dec 7 [Epub ahead of print]
11. Ho CPS, **Lai TYY***. Current management strategy of polypoidal choroidal vasculopathy. *Indian J Ophthalmol* 2018 Dec; 66(12):1727-1735.
12. Hykin PG, Staurenghi G, Wiedemann P, Wolf S, Liew SHM, Desset-Brethes S, Staines H, Li J, **Lai TYY**. Ranibizumab 0.5mg treatment in adolescents with choroidal neovascularization: subgroup analysis data from the MINERVA study. *Retin Cases Brief Rep* 2018 No 2. [Epub ahead of print]
13. Wu W, Li S, Xu H, Liu Y, Wang Y, **Lai TY**, Yin ZQ. Treatment of punctate inner choroidopathy with choroidal neovascularization using corticosteroid and intravitreal ranibizumab. *Biomed Res Int* 2018 Sep 13; 2018:1585803.
14. Chen Y, Sharma T, Li X, Song Y, Chang Q, Lin R, Egger A, Foo A, Gekkieva M, **Lai TYY***. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. *Retina* 2018 Sep 20 [Epub ahead of print]
15. Cheung CMG, Lee WK, Koizumi H, Dansingani K, **Lai TYY**, Freund KB. Pachychoroid disease. *Eye (Lond)*. 2018 Jul 11. [Epub ahead of print]
16. Ng DS, Sun Z, Young AL, Ko ST, Lok JK, **Lai TY**, Sikder S, Tham CC. Impact of virtual reality simulation on learning barriers of phacoemulsification perceived by residents. *Clin Ophthalmol*. 2018 May 11;12:885-893.
17. Zhang X, **Lai TYY**. Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration. *Biomed Res Int*. 2018 Feb 26;2018:9640131.
18. Eldem B, **Lai TYY**, Ngah NF, Vote B, Yu HG, Fabre A, Backer A, Clunas NJ. An analysis of ranibizumab treatment and visual outcomes in the real-world settings: the UNCOVER study. *Graefes Arch Clin Exp Ophthalmol*. *Graefes Arch Clin Exp Ophthalmol*. 2018 May;256(5):963-973.
19. Staurenghi G, **Lai TY**, Mitchell P, Wolf S, Wenzel A, Li J, Bhaumik A, Hykin PG; PROMETHEUS Study Group. Efficacy and safety of ranibizumab 0.5mg for the treatment of macular edema resulting from uncommon causes: twelve-month findings from PROMETHEUS. *Ophthalmology* 2018 Jun; 125(6):850-862.

20. Cheung CM, **Lai TY**, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, Gomi F, Koh AH, Lee WK, Wong TY. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis and management. *Ophthalmology*. 2018 May; 125(5):708-724.
21. Wong TY, Cheung CM, **Lai TY**, Chen SJ, Lee WK, Yoon YH, Iida T, Tueckmantel C, Sowade O, Ogura Y. Efficacy and safety of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration: subgroup analyses from the VIEW trials. *Retina* 2017 Dec 26. doi: 10.1097/IAE.0000000000001986. [Epub ahead of print]
22. **Lai TY***, Cheung CM, Mieler WF. Ophthalmic application of anti-VEGF therapy. *Asia Pac J Ophthalmol (Phila)* 2017 Nov-Dec;6(6):479-480.
23. Ohno-Matsui K, Ikuno Y, **Lai TY**, Cheung CM. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. *Prog Retin Eye Res*. 2018 Mar; 63:92-106.
24. Ng DS, **Lai TY**, Cheung CM, Ohno-Matsui K. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization. *Asia Pac J Ophthalmol (Phila)*. 2017 Nov-Dec; 6(6):554-560.
25. Koh A, **Lai TY**, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK; EVEREST II study group. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. *JAMA Ophthalmol*. 2017 Nov 1;135(11):1206-1213.
26. Cheung GCM, **Lai TYY**, Gomi F, Ruamviboonsuk P, Koh A, Lee WK. Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy. *Asia Pac J Ophthalmol (Phila)*. 2017 Nov-Dec;6(6):527-534.
27. Tan NW, Ohno-Matsui K, Koh HJ, Nagai Y, Pedros M, Freitas RL, Macfadden W, **Lai TY**. Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the RADIANCE study. *Retina*. 2018 Nov; 38(11):2228-2238.
28. Cheung CM, Yoon YH, Chen LJ, Chen SJ, George TM, **Lai TY**, Park KH, Tahija SG, Uy HS, Wong TY. Diabetic macular oedema: evidence-based treatment recommendations for Asian countries. *Clin Experiment Ophthalmol* 2018 Jan;46(1):75-86.
29. **Lai TY***, Staurenghi G, Lanzetta P, Holz FG, Liew SH, Desset-Brethes S, Staines H, Hykin PG, on behalf of the MINERVA study group. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: 12-month results of the MINERVA study. *Retina* 2018 Aug; 33(8):1464-1477.
30. **Lai TY***. An update on Intravitreal Aflibercept in Treating Macular Diseases. *Asia Pac J Ophthalmol (Phila)* 2017 May-Jun;6(3):225-227.

31. Cheung CM, Arnold JJ, Holz FG, Park KH, **Lai TY**, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, Wong TY. Myopic choroidal neovascularization: Review, guidance and consensus statement on management. *Ophthalmology* 2017 Nov;124(11):1690-1711.
32. Ng DS, Yip Y, Bakthavatsalam M, Chen LJ, Ng TL **Lai TY**, Pang CP, Brelen M. Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. *Sci Rep.* 2017 Mar 27;7:45081.
33. Wang Q, Jiang L, Yan W, **Lai TY**. Fundus autofluorescence imaging in the assessment of acute zonal occult outer retinopathy. *Ophthalmologica* 2017;237(3):153-158.
34. Bakthavatsalam M, Ng DS, Lai FH, Tang FY, Brelen ME, Tsang CW, **Lai TY**, Cheung CY. Choroidal structures in polypoidal choroidal vasculopathy, neovascular age-related maculopathy and healthy eyes determined by binarization of swept source optical coherence tomographic images. *Graefe Arch Clin Exp Ophthalmol* 2017 May;255(5):935-943.
35. Ma L, Brelen ME, Tsujikawa M, Chen H, Chu WK, **Lai TY**, Ng DS, Sayanagi K, Hara C, Hashida N, Chan VC, Tam PO, Young AL, Chen W, Nishida K, Pang CP, Chen LJ. Identification of ANGPT2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations. *Invest Ophthalmol Vis Sci* 2017 Feb1;58(2):1054-62.
36. Ng DS, Bakthavatsalam M, Lai FH, Cheung CY, Cheung GC, Tang FY, Tsang CW, **Lai TY**, Wong TY, Brelen ME. Classification of exudative age-related macular degeneration with pachyvessels on en face swept source optical coherence tomography. *Invest Ophthalmol Vis Sci* 2017 Feb 1;58(2):1076-83.
37. Phadikar P, Saxena S, Ruia S, **Lai TY**, Meyer CH, Elliott D. The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. *Int J Retin Vit* 2017;3:1
38. Ma L, Liu K, Tsujikawa M, Chen H, Brelen ME, Chan VC, **Lai TY**, Sayanagi K, Hara C, Hashida N, Tam PO, Young AL, Chen W, Nishida K, Pang CP, Chen LJ. Association of ABCG1 with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese and Japanese. *Invest Ophthalmol Vis Sci* 2016 Oct 1;57(13):5758-63.
39. Jiang L, Chen L, Qiu X, Jiang R, Wang Y, Xu L, **Lai TY**. Choroidal thickness in Chinese patients with non-arteritic anterior ischemic optic neuropathy. *BMC Ophthalmology* 2016 Aug 31;16(1):153.
40. Liu W, Jiang L, Jin Y, Yang B, **Lai TY**. Alveolar rhabdomyosarcoma of the sphenoid sinus mimicking optic neuritis presenting with intermittent visual loss in an adult. *Onco Targets Ther* 2016 Oct 14;9:6333-6.
41. **Lai TY**, Cheung CM. Myopic choroidal neovascularization: diagnosis and treatment. *Retina* 2016 Sep;36(9):1614-21.

42. Saxena S, Ruia S, Cheung CM, **Lai TY**. Spectral domain optical coherence tomography features and classification systems for Diabetic Macular Edema: a review. *Asia Pac J Ophthalmol (Phila)* 2016 Sep-Oct;5(5):360-7.
43. Ng TK, Liang XY, **Lai TY**, Ma L, Tam PO, Wang JX, Chen LJ, Chen H, Pang CP. HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative age-related macular degeneration. *Sci Rep*. 2016 Jun 24;6:28639
44. Holz FG, Tufail A, Leveziel N, **Lai TY**, Lanzetta P, Wong TY, Yu HG, Chen YX, Heinrichs N, Pilz S, Ohno-Matsui K, on behalf of RADIANCE Study Group. Ranibizumab in myopic choroidal neovascularization: a subgroup analysis by ethnicity, age and ocular characteristics in RADIANCE. *Ophthalmologica* 2016;236(1):19-28
45. Ng DS, **Lai TY***, Ng YK, Pang CP. Genetics of Bietti crystalline dystrophy. *Asia Pac J Ophthalmol (Phila)* 2016 Jul-Aug;5(4):245-52
46. Huang L, Zhang H, Cheng CY, Wen F, Tam PO, Zhao P, Chen H, Li Z, Chen L, Tai Z, Yamashiro K, Deng S, Zhu X, Chen W, Li C, Lu F, Li Y, Cheung CM, Miyake M, Lin Y, Gong B, Liu X, Sim KS, Yang J, Mori K, Zhang X, Cackett PD, Tsujikawa M, Nishida K, Hao F, Ma S, Lin H, Chen J, Fei P, **Lai TY**, Tang S, Laude A, Inoue S, Yeo IY, Sakurada Y, Zhou Y, Iijima H, Honda S, Lei C, Zhang L, Zheng H, Jiang D, Zhu X, Wong TY, Khor CC, Pang CP, Yoshimura N, Yang Z. A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy. *Nat Genetics* 2016 Jun;48(6):640-7.
47. Chen LJ, Ma L, Chu WK, **Lai TY**, Chen H, Brelen ME, Rong SS, Young A, Tam P, Zhang M, Pang CP. Identification of PGF as a New Gene for Neovascular Age-related Macular Degeneration in Chinese. *Invest Ophthalmol Vis Sci* 2016 Apr 1;57(4):1714-20.
48. Ng DS, Cheung CY, Luk FO, Mohamed S, Brelen ME, Yam JC, Tsang CW, **Lai TY**. Advances of optical coherence tomography in myopia and pathologic myopia. *Eye (Lond)*. 2016 Jul;30(7):901-16.
49. Sharma T, Fong A, **Lai TY**, Lee V, Das S, Lam D. Surgical treatment for diabetic vitreo-retinal diseases: a review. *Clin Experiment Ophthalmol* 2016 May;44(4):340-54.
50. Marmor MF, Kellner U, **Lai TY**, Melles RB, Mieler MF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). *Ophthalmology* 2016 Jun;123(6):1386-94.
51. Das S, **Lai T**, Liu S, Lam D. The rate of endophthalmitis after intravitreal injections. *Asia Pac J Ophthalmol (Phila)* 2016 Mar-Apr;5(2):165-6.
52. Ohno-Matsui K, **Lai TY**, Lai CC, Cheung CM. Updates of pathologic myopia. *Prog Retina Eye Res* 2016 May;52:156-87.

53. **Lai TY***, Wong RL, Chan WM. Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (An AOS Thesis). *Trans Am Ophthalmol Soc* 2015;113:T81-827.
54. **Lai TY**, Liu S, Das S, Lam DS. Intravitreal injection: technique and safety. *Asia Pac J Ophthalmol (Phila)* 2015 Nov-Dec;4(6):321-8.
55. Shen C, Chen L, Jiang L, **Lai TY**. Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma. *Neurosci Lett* 2015 Jul 23;600:132-136.
56. Ishibashi T, Li X, Koh A, **Lai TY**, Lee FL, Lee WK, Ma Z, Ohji M, Tan N, Cha SB, Shamsazar J, Yau CL, on behalf of the REVEAL Study Group. The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. *Ophthalmology* 2015 Jul;122(7):1402-15.
57. Liu K, **Lai TY**, Ma L, Lai F, Yong AL, Brelen M, Tam P, Pang CP, Chen LJ. Ethnic differences in the association of SERPING1 with age-related macular degeneration and polypoidal choroidal vasculopathy. *Sci Rep* 2015 Mar 24;5:9424.
58. Luk FO, Fok AC, Lee A, Liu A, **Lai TY**. Focal choroidal excavation in patients with central serous chorioretinopathy. *Eye* 2015 Apr;29(4):453-9.
59. Cheng CY, Yamashiro K, Chen LJ, Ahn J, Huang L, Huang L, Cheung CM, Miyake M, Cackett P, Yeo IY, Laude A, Mathur R, Pang J, Sim KS, Koh AH, Chen P, Lee SY, Wong D, Chan CM, Loh BK, Sun Y, Davila S, Nakata I, Nakanishi H, Akagi-Kurashige Y, Gotoh N, Tsujikawa A, Matsuda F, Mori K, Yoneya S, Sakurada Y, Iijima H, Iida T, Honda S, **Lai TY**, Tam P, Chen H, Tang S, Ding X, Wen F, Lu F, Zhang X, Shi Y, Zhao P, Zhao B, Sang J, Gong B, Dorajoo R, Yuan JM, Koh WP, van Dam RM, Friedlander T, Lin Y, Hibberd M, Foo JN, Wang W, Wong CH, Tan GS, Park SJ, Bhargava M, Gopal L, Naing T, Liao J, Ong PG, Mitchell P, Zhou P, Xie X, Liang J, Mei J, Jin X, Saw SM, Ozaki M, Mizoguchi T, Kurimoto Y, Woo SJ, Chung H, Yu HG, Shin JY, Park DH, Kim IT, Chang W, Sagong M, Lee SJ, Kim HW, Lee JE, Li Y, Liu J, Teo YY, Heng CK, Lim TH, Yang SK, Song K, Vithana E, Aung T, Bei JX, Zeng YX, Tai ES, Li XX, Yang Z, Park KH, Pang CP, Yoshimura N, Wong TY, Khor CC. New loci and coding variants confer risk for age-related macular degeneration in East Asians. *Nature Commun* 2015 Jan 28;6:6063.
60. Cheung CM, Yang E, Lee WK, Lee GK, Mathur R, Cheng J, Wong D, Wong TY, **Lai TY**. The Natural history of polypoidal choroidal vasculopathy: a multi-centered series of untreated patients. *Graefes Arch Clin Exp Ophthalmol* 2015 Dec;253(12):2075-85.
61. Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, **Lai TY**, Yu HG, Lanzetta P, Chen Y, Tufail A. Myopic choroidal neovascularization: current concepts and update on clinical management. *Br J Ophthalmol* 2015 Mar;99(3):289-296.

62. Saxena S, Srivastav K, Cheung CM, Ng JY, **Lai TY**.* Photoreceptor inner segment ellipsoid band integrity on spectral domain optical coherence tomography. *Clin Ophthalmol* 2014;8:2507-2522.
63. Liu K, **Lai TY**, Chiang SW, Chan VC, Young AL, Tam PO, Pang CP, Chen LJ. Gender specific association of a complement component 3 polymorphism with polypoidal choroidal vasculopathy. *Sci Rep* 2014 Nov 12;4:7018.
64. **Lai TY**.* Machines and Cutters: Stellaris PC. *Dev Ophthalmol* 2014;54:8-16.
65. Liang XY, Chen LJ, Ng TK, Tuo J, Gao JL, Tam PO, **Lai TY**, Chan CC, Pang CP. FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy. *Eye* 2014 Dec;28(12):1502-10.
66. Ng JY, Luk FO, **Lai TY***, Pang CP. Influence of molecular genetics in Vogt-Koyanagi-Harada disease. *J Ophthalmic Inflamm Infect* 2014 Jul 22;4:20.
67. Mansour AM, Arevalo JF, Kahtani E, Zegarra H, Abboud E, Anand R, Ahmadeih H, Sisk RA, Mirza S, Tuncer S, Tejerina AN, Mataix J, Ascaso FJ, Pulido JS, Guthoff R, Goebel W, Roh YJ, Banker AS, Gentile RC, Martinex IA, Morris R, Panday N, Min PJ, Merce E, **Lai TY**, Massoud V, Ghazi NG. Role of intravitreal anti-vascular endothelial growth factor injections for choroidal neovascularization due to choroidal osteoma. *J Ophthalmol* 2014;2014:210458.
68. Cheung CM, **Lai TY**, Chen SJ, Chong V, Lee WK, Htoon H, Ng WY, Ogura Y, Wong TY. Understanding indocyanine green angiography in polypoidal choroidal vasculopathy: the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy. *Retina* 2014 Dec;34(12):2397-406.
69. Liu K, Chen LJ, **Lai TY**, Tam PO, Ho M, Chiang SW, Liu DT, Young AL, Yang Z, Pang CP. Genes in the High-Density Lipoprotein Metabolic Pathway in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. *Ophthalmology* 2014 Apr;121(4):911-6.
70. Wong RL, **Lai TY**.* The endophthalmitis kit. *Asia-Pacific J Ophthalmol* 2014 March/April;3(2):130
71. Yang MM, **Lai TY***, Luk FO, Pang CP. The roles of genetic factors in uveitis and their clinical significance. *Retina* 2014 Jan;34(1):1-11.
72. Jiang LB, Shen CY, Chen F, Yan WY, **Lai TY**, Wang NL. Clinical features of retinal diseases masquerading as retrobulbar neuritis. *Chin Med J (Engl)* 2013;126(17):3301-6.
73. Yang MM, **Lai TY**, Tam PO, Chiang SW, Ng TK, Pang CP. Association of CFH and SERPING1 polymorphisms with anterior uveitis. *Br J Ophthalmol* 2013 Nov;97(11):1475-80.
74. Wong RL, **Lai TY**.* Polypoidal choroidal vasculopathy: an update on therapeutic approaches. *J Ophthalmic Vis Res* 2013 Oct;8(4):359-71.

75. Zhang X, **Lai TY**, Chiang SW, Tam PO, Liu DT, Chan CC, Pang CP, Chen Z, Chen LJ. Contribution of SNRNP200 sequence variations to retinitis pigmentosa. *Eye* 2013 Oct;27(10):1204-13.
76. **Lai TY***. What's new in uveitis and ocular inflammation. *Asia-Pacific J Ophthalmol* 2013 May/June;2(3):139-140.
77. Luk FO, Chan CK, **Lai TY**. A case of Dengue maculopathy with spontaneous recovery. *Case Rep Ophthalmol* 2013 Jun 8;4(2):28-33
78. Fong AH, **Lai TY***. Long Term Effectiveness of Ranibizumab for Age-Related Macular Degeneration and Diabetic Macular Edema. *Clin Interv Aging* 2013;8:467-483
79. Chen X, Zhao K, Sheng X, Li Y, Gao X, Zhang X, Kang X, Pan X, Liu Y, Jiang C, Shi H, Chen X, Rong W, Chen LJ, **Lai TY**, Liu Y, Wang X, Yuan S, Liu Q, Vollrath D, Pang CP, Zhao C. Targeted sequencing of 179 genes associated with hereditary retinal dystrophies and 10 candidate genes identifies novel and known mutations in patients with various retinal diseases. *Invest Ophthalmol Vis Sci* 2013 Mar 1;54(3):2186-97.
80. Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T, Kim H, **Lai TY**, Lee WK, Li X, Han Lim T, Ruamviboonsuk P, Sharma T, Tang S, Yuzawa M; on behalf of the Expert PCV Panel. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. *Retina* 2013 Apr;33(4):686-716.
81. Chan CK, Wu ZH, Luk FO, Liu DT, Fan AH, Lee VY, **Lai TY**. Clinical characteristics of intermediate uveitis in Chinese patients. *Ocul Immunol Inflamm* 2013 Feb;21(1):56-61.
82. Liu K, Chen LJ, Tam PO, Shi Y, **Lai TY**, Liu DT, Chiang SW, Yang M, Yang Z, Pang CP. Associations of the C2-CFB-RDBP-SKIV2L locus with age-related macular degeneration and polypoidal choroidal vasculopathy. *Ophthalmology* 2013 Apr;120(4):837-43.
83. Nakata I, Yamshiro K, Akagi-Kurashige Y, Miyake M, Kumagi K, Tsujikawa A, Liu K, Chen LJ, Liu DT, **Lai TY**, Sakurada Y, Yoneyama S, Cheng CY, Cackett P, Yeo IY, Tay WT, Vithana EN, Aung T, Matsuo K, Matsuda F, Wong TY, Iijima H, Pang CP, Yoshiura N. Association of genetic variants on 8p21 and 4q12 with age-related macular degeneration in Asian populations. *Invest Ophthalmol Vis Sci* 2012 Sep 25;53(10):6576-81.
84. **Lai TY***. Anti-VEGF therapy for myopic CNV: do we need more evidence? *Retina* 2012 Sep;32(8):1443-5.
85. **Lai TY***, Leung GM. Editorial: Equity and efficiency in healthcare: are they mutually exclusive? *Hong Kong J Ophthalmol* 2012 Sep;16(1):1-4.
86. Mansour AM, Mackensen F, Mahendradas P, Khairallah M, **Lai TY**, Bashshur Z. Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization. *Clin Ophthalmol* 2012;6:1233-1237.

87. Wu ZH, Wong MY, **Lai TY***. Long-term follow-up of intravitreal ranibizumab for the treatment of choroidal neovascularization due to choroidal osteoma. *Case Rep Ophthalmol* 2012 May;3(2):200-204.
88. Yang MM, **Lai TY***, Tam PO, Chiang SW, Chan CK, Luk FO, Ng TK, Pang CP. Complement factor H and interleukin genes polymorphisms in patients with non-infectious intermediate and posterior uveitis. *Mol Vision* 2012 Jul 27;53(8):4969-74.
89. **Lai TY***, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. *Eye* 2012 Jul;26(7):1004-11.
90. Yang MM, **Lai TY**, Tam PO, Chiang SW, Ng TK, Liu K, Pang CP. Association of C2 and CFB polymorphisms with anterior uveitis. *Invest Ophthalmol Vis Sci* 2012 Jul 27;54(8):4969-72.
91. Mansour AM, Arevalo JF, Fardeau C, Hrisomalos EN, Chan WM, **Lai TY**, Ziemssen F, Ness T, Sibai AM, Mackensen F, Wolf A, Hrisomalos N, Heiligenhaus A, Spital G, Jo Y, Gomi F, Ikuno Y, Akesbi J, LeHoang P, Adam A, Mahendradas P, Khairallah M, Guthoff R, Ghandour B, Kucukerdonmez C, Kurup SK. Three-year visual and anatomic results of administering intravitreal bevacizumab in inflammatory ocular neovascularization. *Can J Ophthalmol* 2012 Jun;47(3):269-74.
92. Neelam K, Cheung CM, Ohno-Matsui K, **Lai TY**, Wong TY. Choroidal neovascularization in pathological myopia. *Prog Retin Eye Res* 2012 Sep;31(5):495-525.
93. Wong VW, Chan CK, Leung DY, **Lai TY***. Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection. *Clin Ophthalmol* 2012;6:595-600.
94. **Lai TY***, Chan WM. An update in laser and pharmaceutical treatment for polypoidal choroidal vasculopathy. *Asia-Pac J Ophthalmol* 2012;1:97-104.
95. Wu ZH, Chan RP, Luk FO, Liu DT, Chan CK, Lam DS, **Lai TY***. Review of clinical features, microbiological spectrum, and treatment outcomes of endogenous endophthalmitis over an 8-year period. *J Ophthalmol* 2012;2012:265078
96. Liang XY, **Lai TY**, Liu DT, Fan AH, Chen LJ, Tam PO, Chiang SW, Ng TK, Lam DS, Pang CP. Differentiation of exudative age-related macular degeneration and polypoidal choroidal vasculopathy in the *ARMS2/HTRA1* locus. *Invest Ophthalmol Vis Sci* 2012 May 31;53(6):3175-82.
97. Koh A, Lee WK, Chen LJ, Shen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lam TH. EVEREST Study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. *Retina* 2012 012 Sep;32(8):1453-64.

98. Chan CK, **Lai TY**, Mohamed S, Lee VY, Liu DT, Li CL, Lam DS. Combined high-dose sub-tenon triamcinolone, intravitreal bevacizumab and laser photocoagulation for refractory diabetic macular edema: a pilot study. *Retina* 2012 Apr;32(4):672-8.
99. Yang MM, **Lai TY***, Tam PO, Chiang SW, Chan CK, Luk FO, Ng TK, Pang CP. CFH 184G as a genetic risk marker for anterior uveitis in Chinese females. *Mol Vision* 2011;17:2655-64.
100. Jiang L, Zhang H, Xie J, Jiao X, Zhou H, Ji H, **Lai TY***, Wang N. Application of multifocal visual evoked potentials in the assessment of visual dysfunction in macular diseases. *Eye* 2011 Oct;25(10):1302-9.
101. Luk FO, **Lai TY***. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era: response. *Clin Experiment Ophthalmol.* 2011 Dec;39(9):919.
102. Wong WY, **Lai TY**, Chi SC, Lam DS. Pediatric ocular surface infections: a 5-year review of demographics, clinical features, risk factors, microbiological results and treatment. *Cornea* 2011 Sep;30(9):995-1002.
103. **Lai TY***, Lee GK, Luk FO, Lam DS. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. *Retina* 2011 Sep;31(8):1581-1588.
104. Ng WW, Wu ZH, **Lai TY***. Half dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report. *J Med Case Reports* 2011 May 26;5(1):208.
105. Fok AC, Chan PP, Lam DS, **Lai TY***. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. *Ophthalmic Res* 2011 Mar 10;46(3):160-163.
106. Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, **Lai TY***. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. *Retina* 2011 Jul-Aug;31(7):1378-86.
107. **Lai TY***, Wong RL, Luk FO, Chow VW, Chan CK, Lam DS. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-HAART era. *Clin Exp Ophthalmol* 2011 Mar;39(2):99-104.
108. Marmon MF, Kellner U, **Lai TY**, Lyons JS, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy 2010. *Ophthalmology* 2011 Feb;118(2):415-22.
109. Chan RP, **Lai TY***. Photodynamic therapy with verteporfin for vasoproliferative tumour of the retina. *Acta Ophthalmol.* 2010 Sep;88(6):711-2.
110. **Lai TY**, Chen LJ, Yam GH, Tham CC, Pang CP. Development of novel drugs for ocular diseases: possibilities for individualized therapy. *Per Med* 2010 Jul;7(4):371-86.

111. Chan WM, **Lai TY**. Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asia: A Review. *Hong Kong J Ophthalmol* 2010 Jul;14(1):14-19.
112. Mohamed S, **Lai TY*** Intraocular gas in vitreoretinal surgery. *Hong Kong J Ophthalmol* 2010 Jul; 14(1):8-13.
113. Zhang X, Chen LJ, Law JP, **Lai TY**, Chiang SW, Tam PO, Chu KY, Wang N, Zhang M, Pang CP. Differential pattern of RP1 mutations in retinitis pigmentosa. *Mol Vis* 2010 Jul;16:1353-60.
114. Lee A, **Lai TY***. Central serous chorioretinopathy after solar eclipse viewing: a case report. *Journal of Ophthalmic and Vision Research* 2010;5(3):193-5.
115. Wong RL, Hou P, Choy KW, Chiang SW, Tam PO, Li H, Chan WM, Lam DS, Pang CP, **Lai TY***. Novel and homozygous BEST1 mutations in Chinese patients with Best vitelliform macular dystrophy. *Retina* 2010 May;30(5):820-7.
116. Chen LJ, **Lai TY**, Tam PO, Chiang SW, Zhang X, Lam S, Lam DS, Pang CP. Compound heterozygosity of two novel truncation mutations in RP1 causing autosomal recessive retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2010 Apr;51(4):2236-42.
117. Yang Y, Zhang X, Chen LJ, Chiang SW, Tam PO, **Lai TY**, Chan CK, Wang N, Lam DS, Pang CP. NR2E3 but not NRL mutations are associated with retinitis pigmentosa in the Chinese population. *Invest Ophthalmol Vis Sci* 2010 Apr;51(4):2229-35.
118. Yip YW, Ngai JW, Fok AC, Lai RY, Li H, Lam DS, **Lai TY***. Correlation between functional and anatomical assessments by multifocal electroretinography and optical coherence tomography in central serous chorioretinopathy. *Doc Ophthalmol* 2010 Apr;120(2):193-200.
119. **Lai TY***, Lam CP, Luk FO, Chan RP, Chan WM, Liu DT, Lam DS. Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy. *J Ocular Pharmacol Therapeutics* 2010 Feb;26(1):91-5.
120. **Lai TY***, Chu KO, Chan KP, Ng TK, Yam GH, Lam DS, Pang CP. Alterations in serum fatty acid concentrations and desaturases activities in Bietti crystalline dystrophy unaffected by CYP4V2 genotypes. *Invest Ophthalmol Vis Sci* 2010 Feb;51(2):1092-7.
121. Liu J, Choy KW, Chan LW, Leung TY, Tam PO, Chiang SW, Lam DS, Pang CP, **Lai TY***. Tyrosinase gene (TYR) mutations in Chinese patients with oculocutaneous albinism type 1. *Clin Exp Ophthalmol* 2010 Jan;38(1):37-42.
122. Chan CK, Mohamed S, Lee VY, **Lai TY**, Shanmugam MP, Lam DS. Intravitreal dexamethasone for diabetic macular edema: a pilot study. *Ophthalmic Laser Surg Imag* 2010 Jan-Feb;41(1):26-30
123. Lan C, Tam PO, Chiang SW, Chan CK, Luk FO, Lee GK, Ngai JW, Law JS, Lam DS, Pang CP, **Lai TY***. Manganese Superoxide Dismutase and Chemokine Genes Polymorphisms in Chinese Patients with Anterior Uveitis. *Invest Ophthalmol Vis Sci* 2009 Dec;50(12):5596-600.

124. **Lai TY***. Future directors and developments for Hong Kong Journal of Ophthalmology. *Hong Kong J Ophthalmol* 2009 Dec;13(1):3-4.
125. Lee GK, Wong AL, Luk FO, **Lai TY***. Visual outcome of retinal angiomatous proliferation in Chinese patients following photodynamic therapy or direct laser photocoagulation. *Hong Kong Journal of Ophthalmology* 2009;13(1):5-8.
126. **Lai TY***, Liu DT, Chan KP, Luk FO, Pang CP, Lam DS. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized controlled trial. *Retina* 2009 Oct;29(9):1218-26.
127. Wong VW, Chu KO, Lam PT, Yam GH, **Lai TY***. Late appearance of intracameral ophthalmic ointment globule after uneventful phacoemulsification. *Japanese Journal of Ophthalmology* 2009 Sep;53(5):553-5.
128. Yip YW, Fok AC, Ngai JW, Lai RY, Lam DS, **Lai TY***. Changes in first and second-order multifocal electroretinography in idiopathic macular hole and their correlations with macular hole diameter and visual acuity. *Graefes Arch Clin Exp Ophthalmol* 2010 Apr;248(4):477-84.
129. Mohamed S, Leung GM, Chan CK, **Lai TY**, Lee VY, Liu DT, Li KK, Li PS, Lam DS. Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone. *Clin Experiment Ophthalmol* 2009 Aug;37(6):602-8.
130. **Lai TY***, Ngai JW, Lai RY, Lam DS. Multifocal electroretinography changes in patients on ethambutol therapy. *Eye* 2009 Aug;23(8):1707-13
131. **Lai TY***, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. *Retina* 2009 Jun;29(6):750-6.
132. Wu LL, Yuen HK, Chan CK, **Lai TY**, Chan JK, Cheuk W. Panuveitis as an initial presentation of extranodal NK/T -cell lymphoma. *Leukemia and Lymphoma* 2009 Apr;50(4):648-50.
133. Lam DS, **Lai TY**, Lee VY, Chan CK, Liu DT, Mohammed S, Li CL. Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema: 6-month Results of a Randomized Controlled Trial. *Retina* 2009 Mar;29(3):292-9.
134. **Lai TY***, Chan RP, Chan CK, Lam DS. Effects of the Duration of Initial Oral Corticosteroid Treatment on the Recurrence of Inflammation in Vogt-Koyanagi-Harada Disease. *Eye*. 2009 Mar;23(3):543-8.
135. Luk FO, Kwok AK, **Lai TY**, Lam DS. Presence of crystalline lens as a protective factor for the late development of open angle glaucoma following vitrectomy. *Retina* 2009 Feb;29(2):218-24.
136. Chan WM, **Lai TY**, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. *Br J Ophthalmol*. 2009 Feb;93(2):150-4.

137. Chan WM, **Lai TY**, Lai RY, Liu DT, Lam DS. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. *Retina* 2008 Oct;28(9):1308-13.
138. Tsang CW, Cheung BT, Lam RF, Lee GK, Yuen CY, **Lai TY**, Lam DS. Primary 23-gauge transconjunctival sutureless vitrectomy for rhegmatogenous retinal detachment. *Retina* 2008 Oct;28(8):1075-81.
139. Chan WM, **Lai TY**, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. *Ophthalmology*. 2008 Oct;115(10):1756-65.
140. Mansour AM, Mackensen F, Arevalo JF, Ziemssen F, Mahendradas P, Mehio-Saibai A, Hrisomalos N, **Lai TY**, Dodwell D, Chan WM, Ness T, Banker AS, Pai SA, Berrocal MH, Tohme R, Heiligenhaus A, Bashshur ZF, Kairallah M, Salen KM, Hrisomalos FN, Wood MW, Heriot W, Adan A, Kumar A, Lim L, Hall A, Becker M. Intravitreal bevacizumab in inflammatory ocular neovascularization. *Am J Ophthalmol* 2008 Sep;146(3):410-416.
141. **Lai TY***, Chan WM, Liu DT, Luk OJ, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. *Br J Ophthalmol* 2008 May;92(5):661-666.
142. **Lai TY***, Ngai JW, Lam DS. Multifocal electroretinography: update on its clinical application and future development. *Expert Review of Ophthalmology* 2008 Feb;3(1):85-96.
143. **Lai TY**, Fan DS, Lai WW, Lam DS. Peripheral and posterior pole retinal lesions in association with high myopia: a cross-sectional community-based study in Hong Kong. *Eye* 2008 Feb;22(2):209-213.
144. Chan WM, **Lai TY**, Lau TY, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. *Retina* 2008 Jan; 28(1):71-80.
145. Chan WM, **Lai TY**, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. *Retina* 2008 Jan; 28(1):85-93.
146. **Lai TY***, Lai RY, Ngai JW, Chan WM, Li H, Lam DS. First and second-order kernel multifocal electroretinography abnormalities in acute central serous chorioretinopathy. *Doc Ophthalmol* 2008 Jan; 116(1):29-40.
147. Chan WM, **Lai TY**, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 6-month results of a prospective pilot study. *Ophthalmology* 2007 Dec; 114(12):2190-2196.

148. **Lai TY***, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key methodological items of randomized controlled trials in clinical ophthalmic journals. *Ophthalmic Epidemiology* 2007 Nov-Dec; 14(6):390-398.
149. **Lai TY***, Chan WM, Liu DT, Lam DS. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. *Graefe Arch Clin Exp Ophthalmol* 2007 Dec; 245(12):1877-1880.
150. **Lai TY***, Ng TK, Tam PO, Yam GH, Ngai JW, Chan WM, Liu DT, Lam DS, Pang CP. Genotype-phenotype analysis of Biett's crystalline dystrophy in patients with CYP4V2 mutations. *Invest Ophthalmol Vis Sci* 2007 Dec; 48(11):5212-5220.
151. Lam DS, Chan CK, Mohamed S, **Lai TY**, Lee VY, Liu DT, Li KK, Shanmugam MP. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diffuse diabetic macular edema: 6-month results. *Ophthalmology* 2007 Dec; 114(12):2162-2167.
152. **Lai TY***, Mohamed S, Chan WM, Lai RY, Lam DS. Multifocal Electroretinogram in Dengue Fever Associated Maculopathy. *British Journal of Ophthalmology* 2007 Aug; 91(8):1084-1085
153. Lee GK, **Lai TY***, Chan WM, Lam DS. Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration *Graefe Arch Clin Exp Ophthalmol* 2007 Aug; 245(8):1225-1257.
154. Chan WM, **Lai TY**, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for CNV secondary to central serous chorioretinopathy, punctate inner choroidopathy, or of idiopathic origin. *Am J Ophthalmol* 2007 Jun; 143(6):977-983.
155. Cheung BT, **Lai TY**, Yuen CY, Lai WW, Tsang CW, Lam DS. Results of high-density silicone oil as a tamponade agent in macular hole retinal detachment in patients with high myopia *Br J Ophthalmol*. 2007 Jun; 91(6):719-721.
156. Fok AC, **Lai TY***, Wong VW, Wong AL, Lam DS. Spontaneous resolution of retinal pigment epithelial tears and pigment epithelial detachment following blunt trauma. *Eye* 2007 Jun; 21(6):891-893.
157. **Lai TY***. Osteoporosis-Pseudoglioma Syndrome May Not Be Caused by Persistent Fetal Vasculature - Reply. *Arch Ophthalmol* Mar 2007; 125:433.
158. **Lai TY***. Assessment of macular function by multifocal electroretinography following epiretinal membrane surgery with indocyanine green-assisted internal limiting membrane peeling: reply. *Graefe Arch Clin Exp Ophthalmol* 2007 Feb 21 [Epub ahead of print].
159. Wong VW, **Lai TY***, Lee GK, Wong AL, Leung GM, Lam PTH, Lam DSC. Non-attendance behaviour at a general ophthalmic out-patient clinic in Hong Kong – the patient's perspectives. *Hong Kong Journal of Ophthalmology* 2007 Jan-Feb;10:15-21.

160. Wong VW, **Lai TY***, Lee GK, Lam PTH, Lam DSC. Safety and efficacy of micro-incisional cataract surgery with bimanual phacoemulsification. *Ophthalmologica* 2007;Jan 221:24-28.
161. **Lai TY***, Chan WM, Lai RY, Ngai JW, Li H, Lam DS. The clinical applications of multifocal electroretinography: a systematic review. *Survey of Ophthalmology* 2007;52:61-96.
162. Chan WM, **Lai TY**, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathologic myopia: a pilot study. *Br J Ophthalmol* 2007 Feb;91(2):174-179.
163. Lam DS, Chan CK, Mohamed S, **Lai TY**, Tsang CW, Chan WM, Shanmugam MP. A Prospective Randomized Trial of Different Doses of Intravitreal Triamcinolone for Diabetic Macular Oedema. *Br J Ophthalmol* 2007 Feb;91(2):199-203.
164. **Lai TY***, Kwok AK, Au AW, Lam DS. Assessment of macular function by multifocal electroretinography following epiretinal membrane surgery with indocyanine-green assisted internal limiting membrane peeling. *Graefes Arch Clin Exp Ophthalmol* 2007 Jan;245(1):148-154.
165. Chan CK, Mohamed S, Shanmugam MP, Tsang CW, **Lai TY**, Lam DS. Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. *Br J Ophthalmol* 2006 Sep;90(9):1137-1141.
166. Kwok AK, **Lai TY***, Lee VY, Yeung YS, Chu KO, Pang CP. Effect of application duration of 2% lidocaine jelly on aqueous lidocaine concentration for topical anesthesia in cataract surgery. *Graefe Archives of Clinical and Experimental Ophthalmology* 2006 Sep;244(9):1096-1110.
167. Wong VW, **Lai TY***, Lee GK, Lam PT, Lam DS. A prospective study on trypan blue capsule staining under air versus under viscoelastic. *Eye* 2006 Jul;20(7):820-825.
168. **Lai TY***, Ngai JS, Chan WM, Lam DS. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. *Doc Ophthalmol* 2006 May;112(3):177-187.
169. **Lai TY***, Leung GM, Wong VW, Lam RF, Cheng CO, Lam DS. How evidence-based are publications in clinical ophthalmic journals? *Invest Ophthalmol Vis Sci* 2006 May;47:1831-1838.
170. **Lai TY**, Chan WM, Li H, Lai RYK, Liu DT, Lam DS. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. *Br J Ophthalmol* 2006 Jul;90(7):869-874.
171. Chan WM, **Lai TY**, Tano Y, Liu DT, Li KK, Lam DS. Photodynamic therapy in macular diseases of Asian populations when east meets west. *Jpn J Ophthalmol* 2006 Mar-Apr;50(2):161-169.
172. Tong JP, Chan WM, Liu DT, **Lai TY**, Choy KW, Pang CP, Lam DS. Aqueous Humor Levels of Vascular Endothelial Growth Factor and Pigment Epithelium Derived Factor in Polypoidal

- Choroidal Vasculopathy and Choroidal Neovascularization. *Am J Ophthalmol* 2006 Mar;141(3) 456-462.
173. **Lai TY***, Wong VW, Lam DS. Asymmetrical ocular involvement and persistent fetal vasculature in an adult with osteoporosis pseudoglioma syndrome. *Arch Ophthalmol* 2006 Mar ;124(3):422-423.
174. Chan WM, **Lai TY**, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age-related macular degeneration: a comparative study. *Br J Ophthalmol* 2006 Mar;90(3) 337-341.
175. Wong VW, **Lai TY***, Lam PT, Lam DS. Acute Staphylococcus aureus wound infection after temporal clear corneal phacoemulsification. *Eye* 2006 Feb;20(2):258-260.
176. **Lai TY***, Lee GK, Chan WM, Lam DS. Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion. *Br J Ophthalmol* 2006 Feb;90(2):243-244.
177. Tham CC, Lai JS, Poon AS, **Lai TY**, Lam DS. The result of trabeculectomy with adjunctive intra-operative mitomycin C in Chinese glaucoma patients. *Ophthalm Laser Surg Imaging* 2006 Jan-Feb;37(1):33-41.
178. Kwok AK, **Lai TY***. Indocyanine green-assisted macular pucker surgery – response. *Clin Exp Ophthalmol* 2006 Jan;34(1):96-97.
179. Yip HK, **Lai TY**, So KF, Kwok AK. Retinal ganglion cells toxicity caused by photosensitizing effects of intravitreal indocyanine green with illumination in rat eyes. *Br J Ophthalmol* 2006 Jan;90(1):99-102.
180. Chan WM, Liu DT, **Lai TY**, Li H, Tong JP, Lam DS. Extensive Submacular Haemorrhage in Polypoidal Choroidal Vasculopathy Managed by Sequential Gas Displacement and Photodynamic Therapy: A Pilot Study of One Year Follow-Up. *Clin Exp Ophthalmol* 2005;33(6):611-618.
181. Chan WM, Ohji M, **Lai TY** Liu DT Tano Y, Lam DS Choroidal neovascularisation in pathologic myopia An update in management. *Br J Ophthalmol* 2005 Nov;89(11):1522-1528.
182. **Lai TY***, Chan WM, Li H, Lai RY, Lam DS. Multifocal electroretinographic changes in patients on hydroxychloroquine therapy: a longitudinal study. *Am J Ophthalmol* 2005 Nov;140(5):794-807.
183. Kwok AK, **Lai TY***, Yip WW. Vitrectomy and gas tamponade without internal limiting membrane peeling for myopic foveoschisis. *Br J Ophthalmol* 2005 Sep;89(9):1180-1183.

184. Kwok AK, **Lai TY**, Wong VW. Idiopathic macular hole surgery with indocyanine green-assisted internal limiting membrane peeling versus no internal limiting membrane peeling in Chinese patients: a randomized controlled trial. *Hong Kong Medical Journal* 2005 Aug;11(4):259-266.
185. Kwok AK, **Lai TY***, Yuen KS. Epiretinal membrane surgery with or without internal limiting membrane peeling. *Clin Experiment Ophthalmol* 2005 Aug;33(4):379-385.
186. Wong VW, **Lai TY***, Lam PT, Lam DS. Prioritisation of cataract surgery: a pilot study of using a visual analogue scale versus a priority-setting scoring system. *ANZ Journal of Surgery* 2005 Jul;75(7):587-592.
187. Kwok AK, **Lai TY***, Yeung CK, Yeung YS, Li WW, Chiang S. The effects of indocyanine green and endoillumination on rabbit retina: an electroretinographic and histologic study. *Br J Ophthalmol* 2005 Jul;89(7):897-900.
188. Wong VW, **Lai TY***, Lam PT, Lam DS. Black diaphragm aniridia intraocular lens for aniridia and albinism. *Graefes Arch Clin Exp Ophthalmol* 2005 May;243(5):501-504.
189. **Lai TY**, Chan WM, Lam DSC, Lim E. Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol-related optic neuropathy. *Br J Ophthalmol* 2005 May 89(5):774-775.
190. Fan DS, **Lai TY**, Cheung EYY, Lam DSC. Causes of childhood blindness in school for the visually impaired in Hong Kong. *Hong Kong Medical Journal* 2005 Apr;11(2):85-89.
191. **Lai TY**, Chan WM, Lam DS. Reply to correspondence. Transient visual disturbance after photodynamic therapy by Mennel et al. *Am J Ophthalmol* 2005 Apr;139(4):749.
192. Kwok AK, **Lai TY***, Yam HF, Pang CP. TIMP-1 production in human retinal pigment epithelial cells after laser exposure. *Eye Science* 2005 Mar;21(1):31-37.
193. **Lai TY**, Kwok AK. Reply to comment by Vedantham entitled "ERM, ILM and posterior vitreous cortex in epiretinal membrane surgery" *Am J Ophthalmol* 2005 Feb;139(2):389-90.
194. **Lai TY***, Yeung CK, Kwok AK. Safety testing of indocyanine green and trypan blue using retinal pigment epithelium and glial cell cultures *Invest Ophth Vis Sci* online 30 December 2004
195. Chan WM, Liu DT, **Lai TY**, Li KK, Lee VY, Tsang CW, Lai WW, Lau HH, Tang EW, Mohamed S, Lim E, Lam DS. Update on photodynamic therapy with verteporfin for macular diseases. *Hong Kong Journal of Ophthalmology* 2004 Oct 8(1):23-35.
196. **Lai TY**, Kwok AK, Yeung YS, Kwan K, Woo DC, Yuen KS, Loo AV. Immediate pars plana vitrectomy for dislocated intravitreal lens fragments during cataract surgery. *Eye* 2005 Nov;19(11):1157-62.
197. **Lai TY***, Chan WM, Lam DSC. Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. *Am J Ophthalmol* 2004 Oct;138(4):693-4.

198. Lam DS, Chan CK, Mohamed S, **Lai TY**, Lee VY, Lai WW, Fan DS, Chan WM. **Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a six-month prospective pilot study.** *Eye* 2005 Aug;19(8):885-90.
199. Kwok AK, Yeung CK, **Lai TY**, Chan KP, Pang CP. The effects of trypan blue on cell viability and gene expression in human retinal pigment epithelial cells. *Br J Ophthalmol* 2004 Dec;88(12):1590-1594
200. Wong VW, **Lai TY***, Lam DS. Retinectomy for refractory glaucoma. *Br J Ophthalmol* 2004 Oct;88(10):1352-1353.
201. Kwok AK, **Lai TY**, Li, WWY, Yew DTW, Wong VWY. Trypan blue and indocyanine green assisted epiretinal membrane surgery: clinical and histopathological studies. *Eye* 2004 Sep;18(9):882-888.
202. Kwok AK, **Lai TY**, Li WW, Woo DC, Chan NR. Indocyanine green assisted internal limiting membrane removal in epiretinal membrane surgery: a clinical and histologic study. *Am J Ophthalmol* 2004 Aug;138(2):194-199.
203. **Lai TY***, Yip WW, Wong VW, Lam DS. Multifocal electroretinogram and optical coherence tomography of commotio retinae and traumatic macular hole. *Eye* 2005 Feb;19(2):219-221.
204. Chan WM, Lam DS, **Lai TY**, Liu DT, Li KK, Yao Y, Wong TH. Photodynamic Therapy with Verteporfin for Symptomatic Polypoidal Choroidal Vasculopathy: one-year result of a prospective case series. *Ophthalmology* 2004 Aug;111(8):1576-1584 .
205. **Lai TY**, Leung GM, Wong IO, Johnston JM. Do doctors act on their self-reported intention to computerize? A follow-up population-based survey in Hong Kong. *Int J Med Inform* 2004 June; 73(5):415-431.
206. Leung GM, Yeung RY, **Lai TY**, Johnston JM, Tin KY, Wong IO, Woo PP, Ho LM. Physicians perceptions towards the impact of and willingness to pay for clinical computerization in Hong Kong. *Int J Med Inform* 2004 June; 73(5):403-414.
207. **Lai TY**, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram following photodynamic therapy. *Am J Ophthalmol* 2004 May;137(5):826-833.
208. **Lai TY**, Kwok AK. Reply to comments on Internal limiting membrane staining with various concentrations of indocyanine green dye under air in macular surgeries. *Am J Ophthalmol* 2004 Mar;137(3):589-590.
209. Kwok AK, **Lai TY**. Macular hole surgery with or without indocyanine green stained internal limiting membrane peeling. *International Journal of Ophthalmology* 2004 Feb; 4(1):33-38.

210. Chan WM, Lam DS, Wong TH, **Lai TY**, Kwok AK, Tam BS, Li KK. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization - one-year result of an uncontrolled, prospective case series. *Ophthalmology* 2003 Dec;110(12):2395-402.
211. Chan WM, Lam DS, **Lai TY**, Tam BS, Liu DT, Chan CK. Choroidal Vascular Remodeling in Central Serous Chorioretinopathy after Indocyanine-Green Guided Photodynamic Therapy with Verteporfin: A Novel Treatment at the Primary Disease Level. *Br J Ophthalmol* 2003 Dec;87(12):1453-1458.
212. Kwok AK, **Lai TY**, Yuen KS, Tam BS, Wong VW. Macular hole surgery with or without indocyanine green stained internal limiting membrane peeling. *Clinical and Experimental Ophthalmology* 2003;31:470-475.
213. Chan WM, Lam DS, **Lai TY**, Yuen KS, Liu DT, Chan CK, Chen WQ. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. *Am J Ophthalmol* 2003 Nov;136(5):836-845.
214. Kwok AK, **Lai TY**, Wu RM. Argon laser photocoagulation for the treatment of idiopathic, bilateral, recurrent, diffuse retinal arterial aneurysms. *Ophthalmic Surg Lasers Imaging* 2003 Sep-Oct;34(5):437-439.
215. Kwok AK, **Lai TY**, Chan NR. Epiretinal membrane formation with internal limiting membrane wrinkling after Nd YAG laser membranotomy in Valsalva retinopathy. *Am J Ophthalmol* 2003 Oct;136(4):763-766.
216. McClellan KA, **Lai T**, Grigg J, Billson F. Penetrating keratoplasty in children visual and graft outcome. *Br J Ophthalmol* 2003 Oct; 87(10):1212-1214.
217. Chan WM, Li KK, Liu DT, **Lai TY**, Chong KK, Lam DS. Photodynamic therapy with verteporfin in laser-induced choroidal neovascularization. *Am J Ophthalmol* 2003 Sep;136(3):565-567.
218. **Lai TY**, Kwok AK. Iatrogenic punctate chorioretinopathy after internal limiting membrane peeling. *Am J Ophthalmol* 2003 Aug;136(2):396.
219. Kwok AK, Lee YW, **Lai TY**, Hon C. Laser-induced chorioretinal venous anastomosis in ischemic central retinal vein occlusion. *Br J Ophthalmol* 2003 Aug;87(8):1043-1044.
220. Kwok AK, **Lai TY**, Yew DT, Li WW. Internal limiting membrane staining with various concentrations of indocyanine green dye under air in macular surgeries. *Am J Ophthalmol* 2003 Aug;136(2):223-30.
221. Kwok AK, **Lai TY**. Internal limiting membrane removal in macular hole surgery for severely myopic eyes a case-control study. *Br J Ophthalmol* 2003 Jul;87(7):885-889.
222. **Lai TY***, Wong VW, Leung GM. Is ophthalmology evidence-based? A clinical audit of the emergency unit of a regional eye hospital. *Br J Ophthalmol* 2003 Apr;87(4):385-90.

223. Kwok AK, **Lai TY**, Yip WW. Correlation of clinical and optical coherence tomography findings in postoperative macular hole closure status. *Ophthalmic Surg Lasers Imaging* 2003 Jan-Feb;34(1):25-32.
224. Kwok AK, **Lai TY**, Chan WM, Woo DC. Indocyanine green assisted-retinal internal limiting membrane in stage 3 or 4 macular hole surgery. *Br J Ophthalmol* 2003 Jan;87(1):71-4.
225. Yam HF, Kwok AK, Chan KP, **Lai TY**, Chu CK Pang CP. The effects of indocyanine green and illumination on gene expression in human retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci* 2003 Jan;44(1):370-7.
226. Kwok AK, Li KK, **Lai TY**, Lam DS. Pars plana vitrectomy in the management of retained intravitreal lens fragments after cataract surgery. *Clin Experiment Ophthalmol* 2002 Dec;30(6):399-403.
227. Kwok AK, **Lai TY**, Chan CW, Neoh EL, Lam DS. Polypoidal choroidal vasculopathy in Chinese patients *British Journal of Ophthalmology* 2002 Aug;86(8):892-897.
228. Kwok AK, **Lai TY**. Internal limiting membrane peeling in macular hole surgery. *Ophthalmology* 2002 May 109(5):822.
229. Kwok AK, Lam SW, **Lai TY**, Lam DS. Endophotocoagulation to retinal pigment epithelium as an adjuvant therapy in the management of retinal detachment due to a highly myopic macular hole. *Ophthalmic Laser & Surgery* 2002 Mar-Apr;33(2):155-157.
230. Kwok AK, Li WW, Pang CP, **Lai TY**, Yam GH, Chan CW, Chan NR, Lam DS. Indocyanine green staining and removal of internal limiting membrane in macular hole diseases surgical technique, histology and outcome. Reply in *Am J Ophthalmol* 2002 April 133(4):588.
231. Lee VY, Cheung BT, **Lai TY**, Yuen CY, Kwok AK, Lam DS. Acrylic intraocular lens placement in conjunction with pars plana vitrectomy. *Am J Ophthalmol* 2002 Apr;133(4):586.
232. Kwok AK, Li WW, Pang CP, **Lai TY**, Yam GH, Chan CW, Chan NR, Lam DS. Indocyanine green staining and removal of internal limiting membrane in macular hole diseases surgical technique, histology and outcome. *Am J Ophthalmol* 2001 Aug 132(2):178-183.
233. **Lai TY**, Kwok AK, Fung KC, Chan WM, Fan DS, Lam DS. Stenotrophomonas maltophilia endophthalmitis following penetrating eye injury by a wooden splinter. *Eye* 2001 June 15(3):353-354.
234. Kwok AK, **Lai TY**, Neoh EL, Lee RW, Lam DS. **Sub-Tenon's injection for posterior segment surgery.** *Ophthalmology* 2001 June 108(6):1006-1007.
235. **Lai TY**, Kwok AK, Lam DS. Automated Surgical Equipment Requires Routine Disinfection of Vacuum Control Manifold to Prevent Postoperative Endophthalmitis. *Ophthalmology* 2001 April 108(4):636-637.

236. Kwok AK, **Lai TY**, Cheng AC, Lam DS. Massive subretinal haemorrhage associated with central serous chorioretinopathy . *Eye* 2001 Feb; 15:121-123.
237. Kwok AK, Li JZ, **Lai TY**, Chan WM, Bhende P, Lam DS. Multifocal electroretinographic and angiographic changes in preeclampsia *Br J Ophthalmol* 2001 Jan; 85(1):111-112.
238. Kwok AK, **Lai TY**, Shetty NS, Lam DSC. Central serous retinopathy complicated by massive bilateral subretinal hemorrhage. *Br J Ophthalmol* 2000 Aug;84(8):936-937.
239. Leung AT, **Lai TY**, Cheng LL, Li CK, Ng JSK, Lam DSC. Primary orbital Ewing's sarcoma report of a case and review of the literature. *Eye* 1999 Dec;13:703.
240. **Lai TY**, Lam DS, Leung AT. Primary Orbital Ewing Sarcoma in a Middle-aged Woman. *Arch Ophthalmol* 2000 Apr;118(4):592.
241. **Lai TY**, Kwok AK, Lam DS, Bhende P. Progression of Diabetic Retinopathy after Endophthalmitis. *Ophthalmology* 2000 Apr;107(4):619-621.